By Gwendolyn Wu
Published October 6, 2026
In a move that provides a significant infusion of confidence into the European life sciences ecosystem, Netherlands-based venture capital giant Forbion announced on Tuesday that it has successfully closed 2.3 billion euros—approximately $2.6 billion—across two new investment vehicles. This fundraising achievement, the largest in the firm’s history, arrives at a critical juncture for a European biotech industry currently grappling with capital shortages, regulatory hurdles, and a mounting sense of urgency regarding its global competitiveness.
The new capital, split between Forbion Growth Opportunities IV and Forbion Ventures Fund VIII, is earmarked to support as many as 30 nascent life sciences companies. For a sector that has watched a significant portion of its research and development talent and investment flow toward the United States and China, Forbion’s latest "dry powder" represents more than just a financial milestone; it serves as a strategic bulwark against a deepening innovation deficit.
The Strategic Deployment of Capital
Forbion’s strategy remains steadfastly focused on identifying high-potential, early-stage biotechnology firms that possess the scientific rigor to address unmet medical needs. According to the firm, the deployment of this $2.6 billion has already commenced, with initial investments flowing into ventures such as the thyroid eye disease specialist Sling Therapeutics and the immuno-oncology firm Solstice Oncology.
The firm’s approach to portfolio management is characterized by a "cradle-to-market" philosophy. Since its inception, Forbion has supported 142 companies, playing a pivotal role in bringing 21 medical products to market. This track record of success has solidified its status as the largest venture fund in Europe dedicated exclusively to life sciences.
The latest fundraising effort notably exceeded the firm’s initial targets, signaling continued appetite from institutional investors despite the broader macroeconomic volatility. The investor syndicate backing these new funds includes heavyweights such as Dutch pension managers MN and PGGM, the Kauffman Foundation, Germany’s KfW Capital, and the pharmaceutical giant Eli Lilly. Following this close, Forbion’s total assets under management have swelled to an impressive 7.5 billion euros.
A Chronology of Growth: From Resilience to Dominance
To understand the significance of Forbion’s latest raise, one must look at the firm’s trajectory over the past several years.
- 2022–2023: The Foundation of Activity. As the global biotech market faced post-pandemic adjustments, Forbion emerged as one of the most active investors in the space. BioPharma Dive data confirms at least 55 public investments since the start of 2022, demonstrating an aggressive commitment to clinical-stage development.
- 2024: The $2.2 Billion Milestone. Forbion set a high bar in 2024 by securing $2.2 billion in funding. This capital proved essential for the success of several high-profile portfolio companies, including the acquisition of Capstan Therapeutics by AbbVie, the purchase of Mariana Oncology by Novartis, and the acquisition of Aiolos Bio by GSK.
- 2025: The IPO Wave. The firm’s maturation strategy bore fruit as portfolio companies like MapLight Therapeutics successfully navigated the complex path to initial public offerings, proving that the European venture pipeline could generate exit opportunities capable of capturing international investor interest.
- 2026: The $2.6 Billion Expansion. With the latest funds secured, Forbion is now positioned to act as a primary stabilizer for the European market, filling the gap left by more risk-averse traditional banking institutions.
Supporting Data: Why Europe Needs This Capital
The necessity for Forbion’s massive infusion is underscored by a sobering reality: European biotech is losing its relative share of global R&D. Data indicates that while innovation remains high, the commercialization of that innovation is lagging.
The European ecosystem faces a "capital chasm." While early-stage seed funding remains relatively accessible, the "growth-stage" funding—required to move from initial clinical trials to large-scale, late-stage testing—is significantly thinner in Europe than in the U.S. or China. This shortage often forces European startups to move their operations across the Atlantic to secure the necessary funding for Phase 3 trials, effectively stripping Europe of the economic benefits of its own scientific breakthroughs.
Forbion’s ability to raise 2.3 billion euros acts as a necessary counterweight to these trends, ensuring that some of the most promising research teams have the resources to stay in Europe, build their infrastructure locally, and contribute to the regional tax base and talent pool.
Official Responses: The View from the Top
Sander Slootweg, co-founder and managing partner at Forbion, acknowledged the difficult market climate during the announcement. "Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," Slootweg stated. His comments reflect a broader sentiment within the firm: that in times of scarcity, the role of the venture capitalist must shift from passive observer to active architect of the industry.
However, the firm’s internal success does not mask the external challenges. The biotech sector at large remains critical of the current regulatory and policy environment in the European Union. In September 2026, a coalition of nine prominent board chairs of major European biotech firms published an open letter that sent shockwaves through the Brussels policy establishment.
"Europe has treated medicine as a cost to suppress rather than one of the best investments a government can make," the letter argued. The executives highlighted that the continent is conducting fewer clinical trials than it did a decade ago, while China, bolstered by streamlined regulatory frameworks and massive state-led investment, has begun to dominate the landscape of pharmaceutical research.
Implications: The Road Ahead
The success of Forbion’s latest fundraise serves as both a victory and a warning. It is a victory because it proves that there is still significant institutional appetite for high-quality European life sciences. It is a warning because, as the executives noted in their open letter, "Europe’s alarm bells are ringing."
For the European biotech industry, the implications of this new capital are three-fold:
- Retention of Intellectual Property: With $2.6 billion available, more firms will have the runway to reach mid-stage development before needing to partner with or be acquired by Big Pharma. This increases the likelihood that core intellectual property remains rooted in European labs.
- Increased Bargaining Power: As Forbion becomes more capable of providing follow-on funding, its portfolio companies gain leverage when negotiating with global pharmaceutical acquirers. They are no longer "distressed assets" looking for an exit; they are growing companies with legitimate alternatives.
- Pressure for Policy Reform: The sheer size of Forbion’s fund highlights the disparity between private sector initiative and public policy. As the firm continues to deploy capital, the contrast between the vibrancy of their portfolio and the stagnation of the broader European regulatory landscape will likely intensify pressure on EU policymakers to harmonize drug approval processes and improve the continent’s clinical trial infrastructure.
As the industry moves into the final quarter of 2026, all eyes will be on how Forbion chooses to allocate its remaining capital. The firm has set a standard for what is possible, but industry leaders remain clear: venture capital alone cannot solve the systemic issues facing European medicine. For the continent to reclaim its position as a global leader in life sciences, Forbion’s success must be matched by a fundamental shift in how European governments value and regulate the biotech sector.
For now, however, the "alarm bells" have been met with the most potent response possible in the world of finance: a massive, tangible vote of confidence in the future of European science.
About the Author
